Although one-year results of Campath in treating multiple sclerosis showed strong efficacy, Genzyme Corp. and partner Schering AG suspended dosing in a Phase II trial in response to three confirmed cases of severe idiopathic thrombocytopenic purpura (ITP). (BioWorld Today) Read More
